CIRCLE Teaming Profiles
This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the goals of the Critical Illness Immunological Reprogramming and Control Point Learning Engine (CIRCLE) program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.
If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions Portal linked below. Your details will then be added to this page, which is publicly available.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
CIRCLE Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| A | AA | AAA | AAA | AAA | AAA | AAA |
| Joseph Cohn | ACCELINT | joseph.cohn@soartech.com | Ann Arbor, MI | SoarTech develops supervisory control for high-consequence, dynamic systems using agentic AI, causal state reasoning, & uncertainty-aware decision support. Our work spans distributed autonomous system control, interpretable causal modeling, & clinical decision support. We deliver supervisory systems in safety-critical domains, including complex healthcare environments. For TA2, we will build the supervisory layer that, integrates measurement, modeling & intervention under real-world constraints. | We seek TA1 and TA3 collaborators with expertise in inflammatory biology, ICU-to-post-ICU transitions, and organ failure progression to co-develop mechanistically grounded trajectory state models. Partners should include TA1 innovators generating high-resolution inflammatory measurements and TA3 teams advancing actionable modulation strategies. Clinical validation sites and longitudinal datasets are critical to operationalize a supervisory Model-layer architecture | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Alexander Yoshikawa | Adaptyx Biosciences | ay@adaptyx.bio | Menlo Park, CA | Adaptyx has developed a wearable, multi-analyte molecular monitoring platform for continuous, real-time measurement of biomarker panels from dermal interstitial fluid. The system has been demonstrated in humans across multiple analytes and enables high-frequency tracking of metabolites, electrolytes, cytokines, kynurenine metabolites, and drugs. The platform is scalable and supports rapid de novo sensor development for new targets. | Adaptyx seeks ICU clinical partners, systems immunology and digital twin modeling teams, and groups developing immune modulation strategies. Ideal collaborators provide access to critically ill patient cohorts, clinical trial infrastructure, and data integration expertise. We aim to contribute continuous, multiplex molecular data to enable real-time immune trajectory modeling and treatment response monitoring. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Mike Fisher | Alden Scientific | mike@aldenscientific.com | Cambridge, MA | Alden Scientific measures virtually all human biology and uses machine learning to capture the highest resolution picture of human health, providing unique insights and future health state predictions. Our proprietary AI technology integrates and analyzes complex multi-omic data - genetic, proteomic, epigenetic, immunomic and beyond - to reveal what drives health and longevity at the individual level. | We have a unique platform for studying autoantibodies and the B Cell side of the immune system and would be interested in talking to companies studying T Cell responses. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Eva Maria Janerus | Alden Scientific | evamaria@aldenscientific.com | Cambridge, MA | Alden Scientific Immune (formerly Oncimmune) offers next-generation autoantibody profiling which can be integrated into Alden Scientific's multi-omic AI platform alongside proteomics and other 'omics. Our immunoINSIGHTS 2K platform includes a verified panel of 1,920 human-disease-relevant antigens and the largest reference data set of 10,000+ immune profiles across diseases and demographics. We're focused on early detection / risk stratification, and discovering novel targets and pathways. | Researchers and partners with large cohorts looking for immune profiling and AI partnering. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Graeham Douglas | AreteMedical | gdouglas@aretemedtech.com | Cambridge UK | Measurement and data platform for lung inflammation, narrowing, stiffening | Clinical validation, data collection. Complementary data/signal sources | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Matthew Peet | Arizona State University | mpeet@asu.edu | Tempe, AZ | Dynamic modeling of helper-regulatory immune response. Mapping biomarkers to immune state estimates. Parameter identification in immune models using sparse, irregular, and noisy time-series data. | Collaborators to design experimental frameworks for data-based identification of immune state. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Timothy Chou | BevelCloud | tim@bevelcloud.io | Marina del ey, CA | A real-time, privacy-preserving distributed AI cloud infrastructure to enable Disease and Trial-precise AI Agents | AI applications/agents which would benefit from learning on large data sets, while preserving privacy, with the ability to deploy to the point of care. | AP3: Critical Illness Clinical Trials Platform |
| Susan Levinson | BioAegis Therapeutics Inc. | slevinson@bioaegistx.com | North Brunswick, NJ | Normal human protein biomarker of excess inflammation and therapeutic in 600 subject clinical study in critical care/ARDS. | open | AP1: Critical Illness Clinical Data & Analysis Platform, TA1: Measure - Dynamic Immune Descriptor |
| Brian Kelly | Biolinq Incorporated | briankellymd@gmail.com | San Diego, CA | Biolinq focuses on the development of painless, continuous intradermal sensors that can measure multiple analytes important to the immune response in critical illness. | Partners in need of a continuous sensing platform for multiple analytes. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Max Perelman | Biomeme, Inc. | max@biomeme.com | Philadelphia, PA | Biomeme provides a handheld, battery-powered CLIA Waivable POC platform for detection of up to 48 DNA/RNA targets from peripheral and capillary (finger stick) whole blood in <10 minutes. The system can directly connect to LIMS/EMR/EHR through its internal BLW/WiFi chip. Our current research focus is on development of rapid mRNA-based diagnostics for deployment onto our POC platform. | We are a TA1 sub-performer looking to team with an Integrator/Program Lead submitting a Type A proposal. | TA1: Measure - Dynamic Immune Descriptor, AP3: Critical Illness Clinical Trials Platform |
| Kenneth Remy | Case Western Reserve University | kenneth.remy@uhhospitals.org | Cleveland, OH | Our organization integrates AI-driven machine learning with advanced immune endotyping across sepsis, cancer, and critical illness. Using functional assays and multi-omic profiling, we define immune states in real time to identify actionable control points and enable precision deployment of targeted immunotherapies. | We seek partners to deploy and validate these endotyping platforms across diverse clinical settings, enabling predictive enrichment and scalable implementation. Ideal collaborators will support multicenter data integration, rapid clinical trial enrollment, and evaluation of targeted immunomodulatory therapies. | AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| Jonathan Gasson | CereVu Medical, Inc. | jgasson@cerevu.com | San Francisco, CA | CereVu Medical develops objective cerebral oximetry–based biomarkers for pain and dyspnea. We identify reproducible SctO₂ patterns linked to nociception, analgesic response, respiratory distress, and ventilatory load. Using multimodal physiologic data and machine learning, we model transitions to decompensation in critical illness, enabling real-time, quantitative monitoring of neurologic and immunologic stress states. | CereVu seeks clinical partners with expertise in critical care, pulmonology, anesthesiology, and immunology to support validation of objective pain and dyspnea biomarkers in acute illness. Ideal teams have access to ICU populations, experience in complex trial execution, multimodal physiologic data capture, and translational research integrating inflammatory, neurologic, and respiratory endpoints. | TA2: Model - Digital Twin Generator |
| Michael McCurdy | Clairyon | mike@clairyon.com | San Diego, CA | Clairyon offers multimodal AI-powered clinical intelligence solutions to deliver real-time information providers need to intervene when it matters most. Already adopted in multiple major medical centers, Clairyon's inpatient EHR-integrated platform works ceaselessly to predict adverse events, enable targeted interventions, and improve patient outcomes. Further, the Clairyon GenAI mobile health chatbot ingests and analyzes multimodal data to enable ongoing complex care outside of the hospital. | With its particular expertise in critical care, Clairyon seeks clinical sites to deploy its platform in novel manners in diverse settings. Because the platform's ability to integrate complex data from the EHR, wearables, smart devices, and direct patient communication facilitates comprehensive analyses, the Clairyon team seeks partners creating novel "smart" devices that provide further enhanced nuanced understanding of real-world clinical situations. | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Zeno Fox | Continuity | zeno@continuity.bio | Bay Area, CA | Continuous monitoring for molecular biomarkers | - | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Chenkai Ma | CSIRO | chenkai.ma@csiro.au | Sydney, Australia | CSIRO is a multidisciplinary research organisation in Australia. We have strong research records in immunology and data science. We have already built some machine learning driven algorithms to decipher the host immune response to the pathogens, which could be translated for TA1. We are currently also working on the digital twin for ageing. | We are looking for the partners who have owned or recorded hopital datasets such ECG and SpO2 in the ICU and whom would like to utilize these data for building/training digital twin model. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Henry Tse | Cytovale Inc | henry@cytovale.com | South San Francisco, CA, CA | Cytovale's platform is a rapid low cost cellular morphological and biophysical analysis tool specifically designed for the immune system. With a commercialized sepsis diagnostic validating our approach, our technology is critical illness agnostic. We extract 100s of biophysical features per cell to create a rich dataset. Using unsupervised clustering analysis, we identify dynamic immunological groups, making us an ideal TA1 partner to track generalized critical illness trajectories in real-time. | We seek TA2/TA3 partners to leverage our high-dimensional (100+ features) TA1 cellular data mapping immune responses to critical illness. For TA2, we want to combine our unsupervised morphological dataset with other modalities into patient-specific digital twins predicting illness trajectories. For TA3, we seek clinical interventionists to map these dynamic immune states to targeted, FDA-approved immunotherapies, actively modulating control points to reduce ICU stays. | TA1: Measure - Dynamic Immune Descriptor |
| Nicholas Messina | Datavant | nickmessina@datavant.com | Kansas City, MO | Datavant is the United States' largest RealWorldData ecosystem and uses privacy enhancing technology to ensure data is usable compliantly and privately. | Datavant is interested in furthering the CIRCLE program through partnership with entities that generate digital twins, train AI models and deploy ML/AI models for critical care. | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Eugene Chan | DNA Medicine | eugene@rhealth.com | Bedford, MA | We have developed a point-of-care flow cytometer that has been demonstrated in space. | We would be interested in teaming with clinical partners in academia. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Tracy Rausch | DocBox | trausch@docboxinc.com | San Antonio, TX | DocBox has created a critical care MIoT platform which normalizes and aggregiates medical device and EHR data to provide a comprehensive data set of the patient. | Looking for AI and Clinical Partners | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Robert Georgantas | eGlint Proteomics | Robert.Georgantas@eglintbio.com | San Diego, CA | eGlint is advancing ProteoCare™, a rapid, multiplex proteomics point-of-care platform powered by novel thermal-stability biosensors. Our focus is delivering affordable, highly sensitive, <10-minute multi-analyte testing to enable early disease detection, real-time immune monitoring, and decentralized clinical decision-making, expanding access to high-performance diagnostics in community and near-patient settings aligned with ARPA-H CIRCLE goals. | EGlint will be looking for feedback on our approach and for suitability with the CIRCLE program. While will focus on TA1, we currently have partners for TA2 and TA3 that will be part of our proposal. Yet, we would like to also explore partnering opportunities for TA2 and TA3. | TA1: Measure - Dynamic Immune Descriptor |
| Gari Clifford | Emory University | gari@ieee.org | Atlanta, GA | Critical Care Data Platforms, AI, Biobanking, and Predictive Analytics | Partner sites and industrial collaborators with rapid testing technology | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Kevin Tracey | Feinstein Institute | kjtracey@northwell.edu | Manhasset, NY | The body transmits sensory neural signals to the brain about its physiologic, metabolic, and immunologic status. Brain neural networks process this information and respond through reflex outputs that evolution selected to maintain homeostasis. | Expertise in neural network state configurations, processing, and behavior. | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Hongyuan Cao | Florida state University | hcao@fsu.edu | Madison, WI | AI enabled prediction for vital signs with time to event outcome | Domain expert in critical care and other disease | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Yiming Huang | Foli Bio Inc. | yiming@foli.bio | New York, NY | Foli Bio develops Foli-seq, a non-invasive platform that profiles human gut mucosal transcriptome from stool via sensitive host RNA profiling. We build scalable assays and analytics to track immune/epithelial activity longitudinally, discover biomarkers, and predict clinical trajectories. We have preliminary ICU patient feasibility data showing we can capture gut host inflammatory signals relevant to critical illness and immune dysregulation. | We plan to lead TA1 (rapid, repeated immune & inflammation measurements) and seek partners to lead TA2 (mechanistic digital twin development) and TA3 (data/model-guided immune reprogramming), plus collaborators who can provide adult ICU sample access. As a biotech company, we can also lead early commercial transition planning (assay scale-up, regulatory strategy, and partner engagement). | TA1: Measure - Dynamic Immune Descriptor |
| Zoya Gluzman-Poltorak | Forta Bio | Zoya@forta.bio | Livermore, CA | Forta Bio’s ODC™ platform enables selective immune modulation and pathological cell clearance with programmable, receptor-targeted oligonucleotides. Each construct integrates conditional intracellular activation and logic-gated effector action, remaining inert unless disease-specific signals are present—supporting safer, individualized intervention. | Forta Bio seeks drug development partners with capabilities in ICU/critical illness biology, relevant in vivo models, translational pharmacology/tox, and rapid path to IND/early clinical testing for precision immune-modulating therapeutics. | TA3: Modulate - Rational Immune Reprogrammer, TA2: Model - Digital Twin Generator |
| Julia Komissarchik | Glendor, Inc | julia@glendor.com | Draper, UT | Glendor is on a mission to safeguard patient privacy while accelerating medical innovation. With its automated, at-source, at-scale PHI detection technology, Glendor enables healthcare data custodians to share and aggregate multimodal medical data —advancing clinical research, AI model training, and real-world evidence generation without compromising patients’ privacy. Glendor’s customers include government, hospitals, lab networks, pharmaceuticals, AI companies, and medical data lakes. | We provide software for automated detection and de-identification of sensitive health information across multimodal healthcare data, including medical images, scanned documents, PDFs, reports, audio, and video. The system is deployable on-premises or in cloud environments and operates entirely within partner-controlled infrastructure. We seek partners interested in applying privacy controls at the data source, including data generated internally and data contributed by external collaborators. | AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| Johan Paulsson | Harvard Medical School | johan_paulsson@hms.harvard.edu | Boston, MA | High throughput screening of blood cells. Mathematical analyses. Diagnostics. Extraction of microbes from blood and bodily fluids. Advanced optics. Ultraparallel micro and nano-fluidics. | Digital twin work. Immunology. | TA1: Measure - Dynamic Immune Descriptor |
| Joseph Miller | Henry Ford Health | jmiller6@hfhs.org | Detroit and surround metropolitan area, MI | Clinical emergency and critical care research, integration of biomarkers in precision medicine, immunomodulation in critical illness | We have a strong clinical environment for critical care research and are looking for partners in advanced analytics and immunology | AP3: Critical Illness Clinical Trials Platform, AP1: Critical Illness Clinical Data & Analysis Platform |
| Pavol Genzor | Henry Jackson Foundation (HJF) | pgenzor@aceso-sepsis.org | Bethesda, MD | ACESO uses its global clinical network, multi‑omic data, computational modeling, and translational research to identify immune dysregulation in critical illness. By defining host‑response endotypes and linking them to targeted immune‑modulating therapies, ACESO accelerates discovery of disease mechanisms and development of treatments across diverse causes of critical illness. | Ideal collaborators include academic medical centers, public‑health agencies, and biopharma partners providing diverse patients, clinical data, regulatory alignment, and immuno-modulatory innovations. Added value comes from AI and modeling groups, global‑health organizations, technology companies, and patient‑advocacy groups, enabling discovery, validation, and translation of host‑directed therapies. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Ankit Sakhuja | Icahn School of Medicine at Mount Sinai | ankit.sakhuja@mssm.edu | New York, NY | At Mount Sinai, we conduct cutting edge research in critical care, immunology and actionable AI. We have developed a longitudinal ICU Datamart that harmonizes high resolution multimodal data for critically ill patients across the health system. Our work centers around causal inference, reinforcement learning and agent systems to estimate treatment effects, optimize intervention timing and dosing, and simulate clinical decision strategies. | We seek teaming partners with established small and large animal models of critical illness, including sepsis and multi organ dysfunction, and demonstrated expertise in immune modulation studies. Capabilities should include IACUC approved translational protocols, ICU analogous physiologic monitoring in animals and experience aligning preclinical outcomes with computational modeling. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Maksym Krutko | imec USA | max.krutko@imec-int.com | Cambridge, MA | Imec is a world leading research and innovation center in nanoelectronics and digital technologies focused on advanced semiconductor & system scaling, silicon photonics, AI, sensing, and health applications. Imec conducts interdisciplinary research at the intersection of engineering, data science, and medicine, and has extensive experience collaborating with academic medical centers, research universities, industry partners, and public funding agencies in largescale, multiinstitutional programs | imec’s research capabilities align with the program’s emphasis on quantitative, longitudinal immune characterization, model informed decision-making, and scalable translational platforms, with relevance to Technical Areas TA1 (Measure) and TA2 (Model). | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Imanuel Lerman | InflammaSense, UCSD | ilerman@inflammaSense.com | La Jolla, CA | InflammaSense has made significant strides in advancing its technology and securing critical support for its growth. The company has successfully navigated the regulatory landscape, obtaining a Non-Significant Risk (NSR) determination and completing key Pre-Submissions for the envisioned clinician decision support system; it focused on critical care infectious and inflammatory diagnostics using Autonomic Neurography (ANG) and miRNA technologies. These technologies are core to TA1. | We are seeking partners in TA2 and TA3. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Tim Sweeney | Inflammatix | tim@inflammatix.com | Sunnyvale, CA | Inflammatix develops rapid transcriptomic signatures for acute and critical illness, and can deploy them on our FDA-cleared Myrna(TM) device. We are an industry leader in understanding molecular subtypes of critical illness. We also have gathered likely the world's largest transcriptome database of critical illness. With academic partners, we have recently published on consensus endotypes of critical illness (Moore et al., Nature Medicine, 2025). | Inflammatix and our associated teaming partners are looking for additional clinical study sites, groups experienced in building digital twins, and groups deploying sophisticated algorithms into the EHR. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Luca Emili | InSilicoTrials | luca.emili@insilicotrials.com | Wilmington, DE | We provide a commercial deployed cloud platform (US and worldwide) enabling partners to develop, integrate, and productize computational models, and digital twin for in silico trials, including critical illness and immunomodulation. Leveraging our own scientific capabilities, we also develop models across multiple theraputic areas, making them accessible to non-expert user through multi-model workflow orchestration supporting FDA compliance submission. We perform in the ARPA-H Catalyst program | InSilicoTrials seeks teaming partners with expertise in: clinical management of critically ill patients (ICU, trauma, burn, sepsis); mechanistic computational modeling of immune-inflammatory pathophysiology; biomarker data acquisition, and multi-omics; and adaptive clinical trial design. We welcome partners who can co-develop digital twin models to be hosted and productized on our platform, enabling seamless integration into FDA compliant in silico trials workflows for the CIRCLE program. | AP2: FDA-compliant Digital Twin Platform, TA2: Model - Digital Twin Generator |
| Stefano Finazzi | Istituto di Ricerche Farmacologiche Mario Negri IRCCS | stefano.finazzi@marionegri.it | Milan, Italy | The Laboratory of Clinical Data Science coordinates the GiViTI network, which is partner of the International ICU network LOGIC. For GiViTI we manage a registry of over 200 ICUs and an EHR-based data collection system used in 80 ICUs in Italy. Its mission is to assess and improve quality of care and conduct clinical research in the field of critical care medicine. Activities include regulatory management, software development for data collection, and statistical and machine-learning analyses. | We seek partners to complement our expertise, including immunology groups with accredited labs for advanced immunophenotyping and multi‑omics assays; teams skilled in developing advanced digital‑twin systems integrating mechanistic and machine‑learning models for real‑time immune‑response modeling; and international ICU collaborators to complement our existing clinical sites for multicenter studies. | AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| Rachel Clipp | Kitware | rachel.clipp@kitware.com | Carrboro, NC | Kitware is a research and development company with a history of developing and maintaining open source solutions, including the digital twin platform, Pulse Physiology Engine. Our team of medical computing experts has significant experience with multi-scale, multi-physics models of the human response to disease, trauma, and treatment. Our open-source computaional physiology engine can be leveraged to create a digital twin of the immune response during critical illness. | We are looking to join a TA2 or AP2 team to create a digital twin of the immune response. We are looking for a team that include high-fidelity models of the immune response and ICU clinical partners that can supply medical expertise and data for model development and validation. | TA2: Model - Digital Twin Generator, AP2: FDA-compliant Digital Twin Platform |
| Diego Rey | Maiten | diego@rey.bio | San Francisco, CA, CA | Endotype identification and therapeutic development. | Reducing mortality and morbidity in sepsis and ARDS. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer, AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| Matt Maciejewski | MatGen LLC | matt@matgenlabs.com | Cambridge, MA | MatGen builds hybrid mechanistic + ML digital twins of biological and chemical systems, integrating physics-based models, omics data, and experimental outputs into iterative design platforms. We implement lab-in-the-loop workflows where models propose experiments, data updates the twin, and cycles optimize molecules, materials, or processes under multi-objective constraints. | Experience in quick experimental iteration and developing high-volume measurements that can be then modeled. | TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Seife Yohannes | MedStar Health Research Institute | seife.yohannes@medstar.net | Washington, DC, DC | MedStar Health Research Institute is involved in several immunological and clinical trials. | Looking for a basic science research expert and lab. We will provide the clinical platform and trial patients. | AP3: Critical Illness Clinical Trials Platform, AP3: Critical Illness Clinical Trials Platform |
| Anand Muthusamy | Melody FRO | anand@convergentresearch.org | Los Angeles, CA | As a focused research organization, we coordinate and execute R&D projects in continuous molecular monitoring and design closed-loop interventions. We engineer new biosensors and sampling schemes to address different compartments with ~minute resolutions. We develop mechanistic, interpretable physiological models that incorporate immune and cardiometabolic biomarkers and are aware of drug titration (closed loop). We share tools openly and develop commercial pathways for sustainability. | Research teams with expertise in relevant animal models; biotech companies with specialty in rapid drug delivery systems or nerve stimulation; clinical teams who treat critically ill adult patients across diverse etiologies and have run adaptive trials. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Michelle Gong | Montefiore Medical Center | MGong@Montefiore.org | Bronx, NY | Prediction and prevention of acute organ failure and critical illness and its complications. Our research is focused on the fact that critical illness can occur anywhere in the hospital from the emergency department to hospital floor to the intensive care unit. Our research harnesses the electronic health record to create an acute learning health system to facilitate observational studies and clinical trials focused on improving outcomes and recovery in patients with acute critical illnesses. | Multicenter large cohorts of hospital wide critical illness for developing embedded precision approaches to the prevention and treatment of acute critical illness and emergencies | AP3: Critical Illness Clinical Trials Platform, AP1: Critical Illness Clinical Data & Analysis Platform |
| Mohammed Eslami | Netrias, LLC | meslami@netrias.com | North Bethesda, MD | Our organization offers AI-driven aggregation of heterogeneous clinical and biological datasets to support multi-institutional research. We provide large curated data products along with including AI-based query tools, to accelerate modeling and analysis. By ensuring FAIR principles and HIPAA-compliant de-identification, we guarantee a secure, interoperable database and tools that meets strict standards for ICU-integrated clinical care. | We are looking for partners capable of hosting a multi-institutional, high-security environment. Domain and standard experts would also be welcomed. | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Gilles Clermont | NOMA AI, Inc. | g.clermont@noma.ai | Pittsburgh, PA | We do multimodal machine learning leveraging EHR and high-resolution physiology signals, in real-time. We are developing xAI tools to promote end-user trust. We also focus on system implementation, reliability and usability, emphasizing clinical decision support within existing clinical workflows. We are also familiar with neural ODE and existing efforts at mechanistic simulations of the inflammatory response. We are also familiar with the FDA clearance process. | Although we can leverage very large datasets, we believe that additional point-of-care bioassays (e.g. sepsis on a chip or POC immunograms) will greatly enhance biomarker driven therapy, as well as monitoring response to therapy. Current approaches ML approaches to optimize therapies are likely fundamentally flawed and would greatly benefit from solid mechanistic underpinnings. Partners with extensive experience in adaptive RCT design of sepsis would be invaluable. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Roger Narayan | North Carolina State University | roger_narayan@ncsu.edu | Raleigh, NC | Our research group specializes in biosensor development and diagnostics for critical illness, with particular emphasis on microneedle-based minimally invasive platforms capable of real-time biomarker monitoring. We are integrating machine learning and AI-enhanced signal processing to improve diagnostic specificity and enable patient stratification. | TA2 expertise in mechanistic, multiscale computational modeling and digital twin development for immune/inflammatory systems; TA3 expertise in immunomodulatory therapeutics; clinical ICU access; regulatory and commercialization experience | AP1: Critical Illness Clinical Data & Analysis Platform, TA1: Measure - Dynamic Immune Descriptor |
| Donghoon Lee | Omphalos Lifesciences Inc | donghoon.lee@omphaloslifesci.com | Dallas, TX | Omphalos excels in system-level, fully kinetic digital twin development, cross-TA integration, and mechanistic control point discovery. We build biologically grounded, data-trained hybrid models that integrate multiscale, spatiotemporal, multimodal data to simulate immune dynamics and therapeutic modulation. Our scalable framework has been tested in viral and bacterial systems and dyslipidemia human disease models. | We seek strong TA1 and TA3 partners to complement our modeling leadership. For TA1, we prioritize ICU teams capable of high-frequency, multiplexed, tissue-attributed immune biomarker acquisition and longitudinal sampling in adult pulmonary ICU patients. For TA3, we seek collaborators with adaptive trial execution and FDA-facing experience in immunomodulatory and digital health interventions. | TA2: Model - Digital Twin Generator |
| Nicusor Iftimia | PHYSICAL SCIENCES INC. | nicusor.iftimia@gmail.com | Andover, MA, MA | TA1 - Non-Invasive Wearables for Inflammation Monitoring; TA2- Dev of digital twin models | Clinical partners | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Carlos Lopez-Espina | Prenosis | carlos.lopez-espina@prenosis.com | Chicago, IL | Prenosis is a biology-based tech company improving outcomes in time-critical, high-mortality conditions by tailoring care to each patient’s biology. Using the NOSIS biobank and deep proteomics, the Immunix EHR-integrated platform, and AI-biomarkers (diagnostic, prognostic, predictive), we deploy workflow-integrated decision tools at scale, and precisely match patients to therapeutics to de-risk development, accelerate precision clinical trials, and advance novel biomarker-guided therapies. | Prenosis seeks partners that accelerate precision medicine in acute care: (1) therapeutic partners with immunomodulator assets that can be matched to biology using our NOSIS-driven AI biomarkers; (2) academic collaborators to advance discovery and validation on the NOSIS dataset; and (3) nstrument and assay developers who want to extend the clinical reach of their protein-measurement platforms by integrating them with Prenosis AI-biomarkers into an end-to-end solution for critical illness. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Paul Henderson | Quantum Leap Healthcare Collaborative | p.henderson@quantumleaphealth.org | San Francisco, CA | Platform clin ical trials in ARDS and Breast Cancer | CIRCLE Teams that can leverage our I-SPY-ARDS platform trial capabilities | AP3: Critical Illness Clinical Trials Platform, AP2: FDA-compliant Digital Twin Platform |
| Juliane Sempionatto | Rice University | jsemp@rice.edu | houston, TX | I am an assistant Prof at Rice University working with wearable and point of care biosensors for tracking immune system, including IL-6, IL-8, TNFa biosensors for ISF, saliva and sweat | We are seeking collaborators to integrate our wearable device as a user interface for the early-detection algorithm. By combining continuous molecular biomarker tracking with machine-learning inference, the wearable can provide actionable early alerts. In addition, biosensor-derived physiological signatures can be leveraged to personalize the model and improve performance over time. | TA1: Measure - Dynamic Immune Descriptor, AP3: Critical Illness Clinical Trials Platform |
| Juliane Sempionatto | Rice University | jsemp@rice.edu | Houston, TX | I am an assistant professor from Rice University, working on wearable biosensors and point of care devices. I am currently developing a biosensor (for ISF, sweat or saliva) for the detection of IL-6, IL-8, and TNFa for tracking the immune system. | I am looking for a team to integrate my sensors and generate data for the AI/machine learning application. My wearable sensors can be the end user interface of the algorithm that can predict outcomes at early stage based on real time data and machine learning | TA1: Measure - Dynamic Immune Descriptor, AP3: Critical Illness Clinical Trials Platform |
| Ioannis Androulakis | Rutgers University | yannis@soe.rutgers.edu | New Brunswick, NJ | Our long-term goal is to enable a trustworthy, deployment-ready ICU decision support that anticipates impeding deterioration early enough to support precision intervention, while explicitly communicating uncertainty, data quality and evidence. The overall objective is to develop and validate agentic ICU digital twins in which modality-specialist predictive agents generate multi-horizon forecast of patient health trajectories and imminent adverse events. | We are looking for additional clinical partners for deployment and testing as well as developer experts. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Garrett Hoard | Schism Labs | garrett@schismlabs.com | San Francisco, CA | Accurate Neuron Simulation for Non-Local Bio-Physical field interactions | Microtubule Researchers looking for safe experimental and classified environments. | TA3: Modulate - Rational Immune Reprogrammer, AP2: FDA-compliant Digital Twin Platform |
| ddot dan | SELFdXb | ddotdan@selfdxb.com | Los Angeles, CA | 2008-2018 successfully proved to counter aging, degenerative issues and avoided spine fusion surgery for human subject. Leading us to solving systems biology questions. To inducing systemic systems biology by expediting microcirculation without active exercise toward whole person health. From blood plasma ecm thru Fascial Communication Network Infrastructure beyond connective tissue. 2/19/2026 | Specialist in systems biology, immune, lymphatic, internal respiratory, mitochondrial systems. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Caroline DeBerry | Tenagrity Solutions | caroline@tenagrity-solutions.com | Fairfax, VA | Hospital-in-one vital sign monitoring RPM (one has already been developed and is / will soon be in use by Mayo) | We are in urgent need of funding. | AP1: Critical Illness Clinical Data & Analysis Platform, AP2: FDA-compliant Digital Twin Platform |
| Elaheh Rahbar | Texas A&M University | erahbar@tamu.edu | College Station, TX | We run an advanced computational cardiovascular lab for trauma, hemorrhagic shock & critical care. Our lab has extensive experience with acquiring real-time hemodynamic and biomarker data from various animal models of shock/injury and develop novel computational methods to evaluate time-dependent changes in inflammation, thrombosis and endothelial function. Our lab has experience with computational FE modeling, statistics, machine learning and artificial intelligence based models. | We'd love to partner with groups who have more clinical data (from humans). | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Vrad Levering | Triple Ring Technologies | vlevering@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products in medtech and life sciences. Our interdisciplinary team (30% PhDs) excels in advancing technologies to FDA approval while working with academic partners. We have engaged with ARPA-H as sub and multiparty. We offer capabilities in device and system integration, project management, biomarker detection instruments, software dev, assay dev, sample prep automation, and complex fluid management. ISO 13485 cert. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission and commercialization, we handle technology development and design, as well as complex system integration. We can contribute to TA1, and act as Team Integrator if appropriate. We are looking for teaming partners that could use our collaborative assistance. We have acted as primary, subcontractor, multiparty team, or vendor on previous submissions. | TA1: Measure - Dynamic Immune Descriptor, Other |
| Paul Vespa | UCLA | pvespa@mednet.ucla.edu | Los Angeles, CA | Neuroimmune biomarker discovery in traumatic brain injury and neurocritical illness | Seeking to define immune targets for reprogramming interventions in traumatic brain injury and neurocritical illness | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Derek Russell | University of Alabama at Birmingham | dwrussell@uabmc.edu | Birmingham, AL | precision trial platform in ARDS | An ideal partner will be facile with high dimensional data and biological systems pathway modelling for estimation of causal contributors to critical illness outcomes | AP3: Critical Illness Clinical Trials Platform, AP1: Critical Illness Clinical Data & Analysis Platform |
| peter morris | University of Alabama at Birmingham | pmorris@uabmc.edu | Birmingham, AL | Adult and pediatric critical care from Emergency Department to hospital discharge and into out-patient clinic, home follow up. We specialize in the effectiveness of frailty assessments, work-life space assessments and rendering continuity of care from critical illness through out patient follow up | Partnering with groups to define end points of critical illness investigational work that have short and longer term patient value | AP1: Critical Illness Clinical Data & Analysis Platform, Other |
| Abu Mosa | University of Alabama at Birmingham | asmosa@uabmc.edu | Birmingham, AL | Aligned to AP1, our research focuses on creating a secure, shared critical-illness clinical data and analytics platform: governed EHR cohort/dataset generation via UAB Medicine’s DataLENS honest-broker model; informatics methods and reusable pipelines through DBIDS; scalable CPU/GPU analytics on the Cheaha supercomputer; and HIPAA-eligible hybrid cloud AI on Azure and Google Cloud under BAAs. | Seeking CIRCLE AP3 partners for AI-driven target trial emulation: health systems with ICU EHR/omics and outcomes data; causal inference/TTE methodologists; ML/MLOps teams for scalable, explainable models; and clinical trial/intervention groups to prospectively validate findings and support translation/commercialization. | AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| James Ford | University of California San Diego | jaf020@health.ucsd.edu | San Diego, CA | Sepsis phenotyping, machine learning based sepsis diagnostic assistance, precision sepsis therapeutic modeling | Partners can help with TA3: Testing of immunomodulatory interventions in the context of critical illness | TA1: Measure - Dynamic Immune Descriptor, TA1: Measure - Dynamic Immune Descriptor |
| Ksenia Zlobina | University of California Santa Cruz | kzlobina@ucsc.edu | Santa Cruz, CA | Complex large scale data analysis, including time-series transcriptomics, proteomic biomarker search for predicting critical health states, computational biology, mathematical modeling, dynamical systems in biology, critical states. | Clinical collaborator that investigates specific illness of critical health state, interested in early prediction of health risks, with availability to critical patient cohorts. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Yosuke Tanigawa | University of California, Los Angeles | tanigawa@ucla.edu | Los Angeles, CA | The UCLA Tanigawa Lab investigates the interindividual differences in disease. To model disease heterogeneity, we develop statistical models and computational tools for biologically grounded digital twins using genetic, multi-omic, and clinical data. We have built robust genetic prediction models across 800+ human traits. Our goal is to develop interpretable AI/ML tools to nominate the most effective disease intervention strategy and advance precision medicine. | We seek collaborators in critical care medicine, immunology, and critical care to validate the digital twin system for their real-time immune phenotyping in critically ill patients. We are looking for partners with expertise in longitudinal profiling, immunomodulatory interventions, and clinical trial design. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Aaron Meyer | University of California, Los Angeles | ameyer@ucla.edu | Los Angeles, CA | Our research group specializes in computational systems immunology, utilizing tensor factorization to uncover interpretable patterns in high-dimensional molecular data. We focus on integrating longitudinal omics and other molecular measurements to link immunological signatures with patient outcomes. By employing neural ODEs, we model patient trajectories and simulate counterfactuals, creating a mathematical foundation for "digital twins" that predict disease progression. | Interested in groups with novel, rich data sources and who would benefit from modeling to help precisely select and time interventions. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Aashish Priye | University of Cincinnati | aashish.priye@ucmail.uc.edu | Cincinnati, OH | We develop microfluidic and 3D-printed sample-to-answer diagnostic devices: rapid nucleic-acid amplification, biosensor assays, and low-cost point-of-care platforms. Capabilities include photothermal heating, assay integration, and flow/transport modeling to enable robust, fieldable biomarker monitoring. | Seeking partners with critical-care clinical access and longitudinal patient samples; immunology/host-response biomarker expertise; data + modeling teams building patient-specific digital twins; and industry/regulatory partners for cartridge manufacturing, analytical/clinical validation, and deployment studies. | TA1: Measure - Dynamic Immune Descriptor |
| Wolfgang Losert | University of Maryland College Park | wlosert@umd.edu | College Park, MD | Generation of dynamic twin with limited training data. Focus on (1) rapid anomaly detection in multimodal data based on limited training data, and (2) predicting dynamics. | Seeking to partner with experts in measurement | TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Arvind Rao | University of Michigan Ann Arbor | ukarvind@umich.edu | Ann Arbor, MI | We develop computational frameworks for modeling and controlling complex biological systems using multimodal data, digital twins, and trajectory-based state estimation. Our work focuses on immune dynamics, disease progression, and intervention optimization through interpretable AI, systems biology, and decision intelligence methods to enable predictive and personalized healthcare. | We seek partners with expertise in critical care, systems immunology, immune biomarker measurement, and clinical data platforms to support real-time immune state characterization, model validation, and intervention testing. We welcome collaborators with ICU cohorts, translational capabilities, and clinical deployment pathways to enable integrated measurement, modeling, and immune reprogramming solutions. | TA3: Modulate - Rational Immune Reprogrammer, TA2: Model - Digital Twin Generator |
| My Helms | University of Utah School of Medicine | my.helms@hsc.utah.edu | Salt Lake City, UT | Focusing on lung epithelial cell's role in triggering innate immune response and looking at therapeutic intervention for newborn lung injury using preclinical animal model systems and primary human lung cells. | computational modeling | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Xuan Wang | Virginia Tech | xuanw@vt.edu | Blacksburg, VA | Multi-Modal Science Foundation Models (FMs): Systematic integration of multi-modal FMs Interpretability, explainability, and causal inference of science FMs Text data, multi-omics data, brain signal data, … Complex Reasoning and Planning with Language Model Agents: Complex reasoning with large language models (multi-hop, long-context, …) Multi-agent large language models for reasoning and planning Efficient small language models for reasoning and planning | Looking to join a team led by clinical experts | TA2: Model - Digital Twin Generator |
| Isaiah Turnbull | Washington University in Saint Louis | iturnbull@wustl.edu | Saint Louis, MO | My research group integrates molecular and functional immunophenotyping to elucidate the mechanisms driving immune dysfunction in critical illness, including sepsis and trauma. We have established a comprehensive infrastructure for patient recruitment, biospecimen biobanking, and the execution of high-throughput assays capable of identifying signaling abnormalities that underlie critical illness–induced deficits in immune cell function. | Expertise in transcriptomics and computational modeling. Clinical partners with access to additional subjects. | AP1: Critical Illness Clinical Data & Analysis Platform |
| Rajat Dhar | Washington University in St. Louis School of Medicine | dharr@wustl.edu | Saint Louis, MO | Evaluating non-invasive transcutaneous vagal nerve stimulation to modulate the immune system after brain injury | Expertise in digital twins for models of brain injury | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |